180 related articles for article (PubMed ID: 19035483)
1. Genetic and epigenetic inactivation of TNFRSF10C in human prostate cancer.
Cheng Y; Kim JW; Liu W; Dunn TA; Luo J; Loza MJ; Kim ST; Zheng SL; Xu J; Isaacs WB; Chang BL
Prostate; 2009 Feb; 69(3):327-35. PubMed ID: 19035483
[TBL] [Abstract][Full Text] [Related]
2. Aberrant methylation frequency of TNFRSF10C promoter in pancreatic cancer cell lines.
Cai HH; Sun YM; Miao Y; Gao WT; Peng Q; Yao J; Zhao HL
Hepatobiliary Pancreat Dis Int; 2011 Feb; 10(1):95-100. PubMed ID: 21269942
[TBL] [Abstract][Full Text] [Related]
3. Genetic and epigenetic inactivation of LPL gene in human prostate cancer.
Kim JW; Cheng Y; Liu W; Li T; Yegnasubramanian S; Zheng SL; Xu J; Isaacs WB; Chang BL
Int J Cancer; 2009 Feb; 124(3):734-8. PubMed ID: 19004026
[TBL] [Abstract][Full Text] [Related]
4. DNA methylation paradigm shift: 15-lipoxygenase-1 upregulation in prostatic intraepithelial neoplasia and prostate cancer by atypical promoter hypermethylation.
Kelavkar UP; Harya NS; Hutzley J; Bacich DJ; Monzon FA; Chandran U; Dhir R; O'Keefe DS
Prostaglandins Other Lipid Mediat; 2007 Jan; 82(1-4):185-97. PubMed ID: 17164146
[TBL] [Abstract][Full Text] [Related]
5. Identification of novel methylation markers in hepatocellular carcinoma using a methylation array.
Shin SH; Kim BH; Jang JJ; Suh KS; Kang GH
J Korean Med Sci; 2010 Aug; 25(8):1152-9. PubMed ID: 20676325
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic inactivation of TRAIL decoy receptors at 8p12-21.3 commonly deleted region confers sensitivity to Apo2L/trail-Cisplatin combination therapy in cervical cancer.
Narayan G; Xie D; Ishdorj G; Scotto L; Mansukhani M; Pothuri B; Wright JD; Kaufmann AM; Schneider A; Arias-Pulido H; Murty VV
Genes Chromosomes Cancer; 2016 Feb; 55(2):177-89. PubMed ID: 26542757
[TBL] [Abstract][Full Text] [Related]
7. Promoter CpG-Site Methylation of the KAI1 Metastasis Suppressor Gene Contributes to Its Epigenetic Repression in Prostate Cancer.
Lee J; Lee MS; Jeoung DI; Kim YM; Lee H
Prostate; 2017 Mar; 77(4):350-360. PubMed ID: 27813113
[TBL] [Abstract][Full Text] [Related]
8. Protein phosphatase and TRAIL receptor genes as new candidate tumor genes on chromosome 8p in prostate cancer.
Hornstein M; Hoffmann MJ; Alexa A; Yamanaka M; Müller M; Jung V; Rahnenführer J; Schulz WA
Cancer Genomics Proteomics; 2008; 5(2):123-36. PubMed ID: 18460741
[TBL] [Abstract][Full Text] [Related]
9. DNA methylation and aberrant expression of Sprouty1 in human prostate cancer.
Kwabi-Addo B; Ren C; Ittmann M
Epigenetics; 2009 Jan; 4(1):54-61. PubMed ID: 19164898
[TBL] [Abstract][Full Text] [Related]
10. Epigenomic profiling of DNA methylation in paired prostate cancer versus adjacent benign tissue.
Geybels MS; Zhao S; Wong CJ; Bibikova M; Klotzle B; Wu M; Ostrander EA; Fan JB; Feng Z; Stanford JL
Prostate; 2015 Dec; 75(16):1941-50. PubMed ID: 26383847
[TBL] [Abstract][Full Text] [Related]
11. CpG island promoter methylation and silencing of 14-3-3sigma gene expression in LNCaP and Tramp-C1 prostate cancer cell lines is associated with methyl-CpG-binding protein MBD2.
Pulukuri SM; Rao JS
Oncogene; 2006 Aug; 25(33):4559-72. PubMed ID: 16786000
[TBL] [Abstract][Full Text] [Related]
12. DNA Methylation-Mediated Downregulation of DEFB1 in Prostate Cancer Cells.
Lee J; Han JH; Jang A; Kim JW; Hong SA; Myung SC
PLoS One; 2016; 11(11):e0166664. PubMed ID: 27835705
[TBL] [Abstract][Full Text] [Related]
13. Methylation profiling identified novel differentially methylated markers including OPCML and FLRT2 in prostate cancer.
Wu Y; Davison J; Qu X; Morrissey C; Storer B; Brown L; Vessella R; Nelson P; Fang M
Epigenetics; 2016 Apr; 11(4):247-58. PubMed ID: 26890304
[TBL] [Abstract][Full Text] [Related]
14. Dynamic regulation of estrogen receptor-beta expression by DNA methylation during prostate cancer development and metastasis.
Zhu X; Leav I; Leung YK; Wu M; Liu Q; Gao Y; McNeal JE; Ho SM
Am J Pathol; 2004 Jun; 164(6):2003-12. PubMed ID: 15161636
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic regulation of EFEMP1 in prostate cancer: biological relevance and clinical potential.
Almeida M; Costa VL; Costa NR; Ramalho-Carvalho J; Baptista T; Ribeiro FR; Paulo P; Teixeira MR; Oliveira J; Lothe RA; Lind GE; Henrique R; Jerónimo C
J Cell Mol Med; 2014 Nov; 18(11):2287-97. PubMed ID: 25211630
[TBL] [Abstract][Full Text] [Related]
16. Regulation of miR-200c and miR-141 by Methylation in Prostate Cancer.
Lynch SM; O'Neill KM; McKenna MM; Walsh CP; McKenna DJ
Prostate; 2016 Sep; 76(13):1146-59. PubMed ID: 27198154
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic regulation of MDR1 gene through post-translational histone modifications in prostate cancer.
Henrique R; Oliveira AI; Costa VL; Baptista T; Martins AT; Morais A; Oliveira J; Jerónimo C
BMC Genomics; 2013 Dec; 14():898. PubMed ID: 24344919
[TBL] [Abstract][Full Text] [Related]
18. Constitutional promoter methylation and risk of familial melanoma.
Hyland PL; Burke LS; Pfeiffer RM; Rotunno M; Sun D; Patil P; Wu X; Tucker MA; Goldstein AM; Yang XR
Epigenetics; 2014 May; 9(5):685-92. PubMed ID: 24762620
[TBL] [Abstract][Full Text] [Related]
19. SFRP1 repression in prostate cancer is triggered by two different epigenetic mechanisms.
García-Tobilla P; Solórzano SR; Salido-Guadarrama I; González-Covarrubias V; Morales-Montor G; Díaz-Otañez CE; Rodríguez-Dorantes M
Gene; 2016 Nov; 593(2):292-301. PubMed ID: 27570179
[TBL] [Abstract][Full Text] [Related]
20. Association of DSC3 mRNA down-regulation in prostate cancer with promoter hypermethylation and poor prognosis.
Pan J; Chen Y; Mo C; Wang D; Chen J; Mao X; Guo S; Zhuang J; Qiu S
PLoS One; 2014; 9(3):e92815. PubMed ID: 24664224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
